## RARE: Ultragenyx Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.3% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($33.35)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Frazier Life Sciences Management L.P. Acquires 325,000 Shares of Ultragenyx Pharmaceutical Inc. $RARE**
- Source: MarketBeat | 20251214T115120 | Somewhat-Bearish | Relevance: 100%
- Frazier Life Sciences Management L.P. significantly increased its stake in Ultragenyx Pharmaceutical Inc. by 49.3%, now holding 983,715 shares valued at approximately $35.77 million. This makes Ultragenyx its 17th largest position, despite the biopharmaceutical company missing recent quarterly earnings expectations and facing some analyst price target cuts. Institutional investors collectively own a substantial 97.67% of Ultragenyx's stock, though a CFO recently sold a portion of their holdings.

**2. Ultragenyx Pharmaceutical (RARE): Reassessing Valuation After Recent Share Price Rebound**
- Source: Yahoo Finance | 20251214T140953 | Somewhat-Bullish | Relevance: 100%
- Ultragenyx Pharmaceutical's stock has rebounded by 10% in the past month, but its one-year return is still negative. Despite this, a "Most Popular Narrative" suggests the stock is 55.7% undervalued with a fair value of $81.85, attributing this to its advancing clinical pipeline and upcoming data readouts. However, persistent cash burn and potential regulatory delays pose risks to this optimistic valuation.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.36M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (-0.8%)
- JPMORGAN CHASE & CO: 8.3% (+146.0%)
- FMR, LLC: 7.6% (+179.6%)
- Blackrock Inc.: 6.7% (+2.7%)
- Sands Capital Manage: 3.9% (-4.4%)

### Key Risks

1. Elevated short interest (9.5%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Revenue growth strong at 21% YoY. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.5B |
| Beta | 0.16 |
| 52W Range | $25.81 - $46.50 |
| Short Interest | 9.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.24 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 stable at 2.3% (minimal 5-day change). Below STRENGTH zone by 0.7pp (needs >3.0% for momentum thesis). MRS_5 at 1.6% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.31% (CS: 52) | Neutral |
| RSI_14 | 61.2 | Neutral |
| MACD Histogram | 0.13 | Bullish |
| vs SMA20 | 1.049x | Above |
| vs SMA50 | 1.081x | Above |
| vs SMA200 | 1.074x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $36.23
- **Stop Loss:** $33.35 (7.9% risk)
- **Target:** $39.11 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 416
- **Position Value:** $15,071.68
- **Portfolio %:** 15.07%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-12 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.21 | $-1.81 | -49.7% |
| 2025Q2 | $-1.32 | $-1.17 | +11.4% |
| 2025Q1 | $-1.64 | $-1.57 | +4.4% |
| 2024Q4 | $-1.27 | $-1.39 | -9.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*